Major pharmaceutical companies, business associations and experts from the EU and the EAEU discussed a common position on the formation of a single pharmaceutical market from Lisbon to Vladivostok, and also welcomed the accession of the Association of Russian Pharmaceutical Manufacturers to the Lisbon-Vladivostok Initiative
Moscow, April 28, 2021. The first meeting of the expert group on the formation of a single pharmaceutical market (Task Force Pharma) in the space of the European Union (EU) and the Eurasian Economic Union (EAEU) was held at the House of German Economy. The expert group was created within the framework of the Lisbon-Vladivostok Initiative and is aimed at developing a balanced business approach to the formation of a single pharmaceutical market.
A solemn ceremony of the Association of Russian Pharmaceutical Manufacturers (ARPM) joining the Lisbon-Vladivostok Initiative took place on the eve of the meeting of the group
Ulf Schneider, Chairman of the Board of the Lisbon-Vladivostok Initiative, said: «The common economic space from Lisbon to Vladivostok will help the protection of the health of the population of both unions and will become the key to strengthening security in Europe.»
ARPM General Director Victor Dmitriev also stressed: “Today we are experiencing not the best political relations. Experience shows that in such situations it is the people’s diplomacy that becomes the driver of the rapprochement processes. Business represents the most entrepreneurial and mobile segment of the population, therefore this initiative finds support in the business community. In our area, this will allow us to create common rules of the game and common approaches to the development of the pharmaceutical business in the EU and the EAEU, which in its turn will have a beneficial effect on the availability and cost of medicines in the space from Lisbon to Vladivostok.»
At the subsequent meeting of the working group, more than 30 experts from France, Germany, Portugal, Switzerland, Russia and Armenia discussed the issues of harmonization of legislation and outlined the main legislative barriers to the development of the pharmaceutical business. The position paper based on the results of the work of Task Force Pharma will be sent to the leadership of the European Commission and the Eurasian Economic Commission in June 2021.
About the Lisbon-Vladivostok Initiative:
In 2015, an initiative arose in European business circles to promote the idea of creating a single economic space on the territory of the European Union (EU) and the Eurasian Economic Union (EAEU) — the Lisbon-Vladivostok business initiative. The foundation of the Initiative is the need of the business community for economic integration and expansion of economic interaction in the Eurasian space. The initiative already brings together more than 100 companies, as well as major business associations from 12 EU and EAEU member states. In 2020, the Initiative received its organizational form in working bodies: the board and a number of expert working groups in specific areas. Events dedicated to the popularization and further promotion of the Initiative are held on a regular basis. The participants of the events held within the framework of the Initiative are business leaders and owners, officials, as well as authoritative members of the expert community.
More information can be found on the website and social networks: